Chronic thromboembolic pulmonary hypertension (CTEPH), representing group 4 of the classification of pulmonary hypertension (PH), is defined as a symptomatic PH with a mean pulmonary arterial pressure (PAm) of at least 25 mmHg and normal pulmonary arterial occlusion pressure (PAOP ≤15 mmHg) with pulmonary perfusion defects persisting after a 3 months episode of adequate anticoagulation . Furthermore, there is a mechanical obstructive component, potentially amenable by surgery and a variable degree of secondary vasculopathy .
CB Wiedenroth has received speaker fees and/or consultant honoraria from Actelion, Bayer AG, BTG, MSD, and Pfizer.
E Mayer has received speaker fees and/or honoraria for consultations from Actelion, Bayer AG, GSK, MSD, and Pfizer.
- 5.Galié N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46(4):903–75.CrossRefGoogle Scholar
- 17.Mizoguchi H, Ogawa A, Munemasa M, Mikouchi H, Ito H, Matsubara H. Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. Minerva Anestesiol. 2012;5(6):748–55.Google Scholar
- 28.Wiedenroth CB, Olsson KM, Guth S, et al. Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic disease. Pulm Circ. 2018; https://doi.org/10.1177/204589321775312.
- 29.Wiedenroth CB, Ghofrani HA, Adameit MSD. Sequential treatment with riociguat and balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension. Pulm Circ. 2018; in press.Google Scholar